160 related articles for article (PubMed ID: 31988753)
21. Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions.
Chu J; Panfen E; Wang L; Marino A; Chen XQ; Fancher RM; Landage R; Patil O; Desai SD; Shah D; Xue Y; Sinz M; Shen H
Pharm Res; 2023 Nov; 40(11):2567-2584. PubMed ID: 37523014
[TBL] [Abstract][Full Text] [Related]
22. Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats.
Miyake T
Biol Pharm Bull; 2020 Mar; 43(3):384-392. PubMed ID: 31685755
[TBL] [Abstract][Full Text] [Related]
23. Maternal and Fetal Exposure to (-)-Δ
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2023 Mar; 51(3):269-275. PubMed ID: 36446608
[TBL] [Abstract][Full Text] [Related]
24. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
[TBL] [Abstract][Full Text] [Related]
25. Development of a novel
Zhang J; Penny J; Lu JR
Int J Food Sci Nutr; 2020 Aug; 71(5):549-562. PubMed ID: 31847617
[TBL] [Abstract][Full Text] [Related]
26. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
27. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide.
Li Y; Song W; Ou X; Luo G; Xie Y; Sun R; Wang Y; Qi X; Hu M; Liu Z; Zhu L
Drug Metab Dispos; 2019 Mar; 47(3):203-214. PubMed ID: 30602435
[TBL] [Abstract][Full Text] [Related]
28. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
29. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2.
Hosomi A; Nakanishi T; Fujita T; Tamai I
PLoS One; 2012; 7(2):e30456. PubMed ID: 22348008
[TBL] [Abstract][Full Text] [Related]
30. Intestinal absorption mechanisms of 2'-deoxy-2'-β-fluoro-4'-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein.
Liu Y; Liu B; Zhang Y; Peng Y; Huang C; Wang N; Jiang J; Wang Q; Chang J
Eur J Pharm Sci; 2017 Jul; 105():150-158. PubMed ID: 28487144
[TBL] [Abstract][Full Text] [Related]
31. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
32. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
33. Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
Takusagawa S; Ushigome F; Nemoto H; Takahashi Y; Li Q; Kerbusch V; Miyashita A; Iwatsubo T; Usui T
Mol Pharm; 2013 May; 10(5):1783-94. PubMed ID: 23560393
[TBL] [Abstract][Full Text] [Related]
34. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
Oostendorp RL; Buckle T; Beijnen JH; van Tellingen O; Schellens JH
Invest New Drugs; 2009 Feb; 27(1):31-40. PubMed ID: 18449471
[TBL] [Abstract][Full Text] [Related]
35. Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2).
Haslam IS; Wright JA; O'Reilly DA; Sherlock DJ; Coleman T; Simmons NL
Drug Metab Dispos; 2011 Dec; 39(12):2321-8. PubMed ID: 21930826
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
37. Prandial state and biological sex modulate clinically relevant efflux transporters to different extents in Wistar and Sprague Dawley rats.
Gavins FKH; Dou L; Qin Y; Madla CM; Murdan S; Basit AW; Mai Y; Orlu M
Biomed Pharmacother; 2023 Apr; 160():114329. PubMed ID: 36731343
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer resistance protein BCRP (ABCG2)-mediated transepithelial nitrofurantoin secretion and its regulation in human intestinal epithelial (Caco-2) layers.
Wright JA; Haslam IS; Coleman T; Simmons NL
Eur J Pharmacol; 2011 Dec; 672(1-3):70-6. PubMed ID: 22004608
[TBL] [Abstract][Full Text] [Related]
39. Bile Duct Obstruction Leads to Increased Intestinal Expression of Breast Cancer Resistance Protein With Reduced Gastrointestinal Absorption of Imatinib.
Kawanishi T; Arakawa H; Masuo Y; Nakamichi N; Kato Y
J Pharm Sci; 2019 Sep; 108(9):3130-3137. PubMed ID: 31136764
[TBL] [Abstract][Full Text] [Related]
40. Effects of Various Pharmaceutical Excipients on the Intestinal Transport and Absorption of Sulfasalazine, a Typical Substrate of Breast Cancer Resistance Protein Transporter.
Sawangrat K; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
J Pharm Sci; 2018 Nov; 107(11):2946-2956. PubMed ID: 30053556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]